In my last article I summarized my discussions with DelMar Pharmaceuticals’ (Nasdaq: DMPI) President and CEO Saiid Zarrabian and the value proposition DelMar offers investors. To recap, DelMar … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
investing
Exclusive New Feature: MS Biotech Financial Health Score
Hello there, MS Chief Pharmaceutical Officer Chris here. I am elated to share something we have been working diligently on: an objective score to help evaluate biotechnology company. As the first of … [Read more...] about Exclusive New Feature: MS Biotech Financial Health Score
Trade-Ideas for Monday, August 12th, 2019
Trade-Ideas: Thursday, Monday, August 12th, 2019Trade ideas for next week:1) BDSI $4.36* Continuation swing opportunity.* Gained 16% last week.* Released strong earnings last week with strong revenue … [Read more...] about Trade-Ideas for Monday, August 12th, 2019
Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Biopharma Stock Watch July 8th-12
Source: MS Money Moves Overall it was a red week for biotech whereas the greater market (S&P, NASDAQ, and DOW) gained a little under +1% each. In the past 30-days the healthcare sector … [Read more...] about Biopharma Stock Watch July 8th-12
Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
While writing my weekly Biopharma Stock Watch article for our members, I stumbled across an exciting clinical-stage gene therapy company Krystal Biotech (Nasdaq: KRYS). Since we started following KRYS … [Read more...] about Krystal Biotech (NASDAQ: KRYS) is On Track to Bring the First “Off the Shelf” Gene Therapy to Market
Biopharma Stock Watch July 1st-4th
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
To recap, in part 1 we talked about Evolus (Nasdaq: EOLS), a relatively young company (no pun intended) entering the medical aesthetics market. Their first product Jeuveau was approved by FDA in … [Read more...] about Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
Global ESG Portfolios: Part 1
This summer I'm living in Japan, uniquely positioning me to observe some of the key metrics for ESGs through a global lens. This article will be part one of a multi part series covering ESG funds … [Read more...] about Global ESG Portfolios: Part 1
You must be logged in to post a comment.